Abstract
Because prostate cancer has a long latency and high incidence, it is a good target for chemoprevention by agents such as retinoids, antiandrogens, antiestrogens, and vitamin D analogs. Phase II chemoprevention trials are frequently conducted on cohorts of patients with previous cancers or premalignant lesions who are scheduled for prostate cancer surgery; such trials are currently in progress with several agents. Prostatic intraepithelial neoplasia (PIN) can be used as a surrogate endpoint biomarker for prostate cancer incidence. Studies of men with high-grade PIN (HGPIN) are particularly useful in that they require a much smaller cohort of 200–400 patients instead of the 18 000 patients required for typical Phase III trials. Even with a smaller sample size, statistically significant evidence of cancer prevention is achieved due to the high probability of HGPIN progressing to cancer (35–55%). A Bayesian sequential monitoring system allows interim analysis of biomarker modulation as early as the completion of 30 patients. Putting all these strategies together will help inhibit, delay, or modulate the natural history of prostate carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kelloff, G., Lieberman, R., Brawer, M. et al. Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis 2 (Suppl 1), 27–33 (1999). https://doi.org/10.1038/sj.pcan.4500274
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500274
Keywords
This article is cited by
-
High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction
World Journal of Urology (2003)
-
High grade prostatic intraepithelial neoplasia is a disease
Current Urology Reports (2001)